European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC

Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib

Evaxion presents new preclinical data on cytomegalovirus vaccine EVX-V1

HDT Bio Launches Canadian clinical programme for brain cancer treatment

Insilico Medicine and CMS to collaborate further on CNS diseases

Accord BioPharma's second pegfilgrastim biosimilar to NEULASTA approved by US FDA

BiBBInstruments signs first European distribution deal for EndoDrill GI with Palex Spain

Ionis and AstraZeneca's eplontersen Phase 3 ATTR-CM trial misses primary endpoint, subgroup analysis shows nominal benefit

Northwest Biotherapeutics presents updated DCVax-L Phase III trial survival data for glioblastoma

Lynk Pharmaceuticals reports first patient dosed in Phase II clinical trial for vitiligo treatment

HanchorBio plans combination research with late-stage cancer drug resistance specialist InxMed

GE HealthCare and Mayo Clinic launch prostate cancer theranostics research study

Insilico initiates Rentosertib Phase III clinical trial for idiopathic pulmonary fibrosis

Aptamer Group launches Optimer-based Ebola diagnostic programme

Physiomics secures new contracts worth over GBP200,000